Review ArticleHeparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists
Section snippets
Types of HIT
HIT is characterized by a precipitous decline in platelet count by more than 50%, typically presenting 5 to 10 days after heparin exposure. The platelet factor 4 (PF4) protein, located on the platelet cell surface, binds to heparin and leads to activation of lymphocytes and subsequent antibody release. The IgG antibodies in turn bind to the heparin/PF4 complexes, resulting in platelet activation.4 This platelet activation generates prothrombotic particles that further enhance the
Risk Factors for HIT and HITT
HIT most commonly is encountered in surgical patients, and more specifically in cardiac surgery, as heparin exposure is virtually universal. The incidence of HIT is about 10 × as high in patients receiving unfractionated heparin compared with patients receiving low-molecular-weight heparin (LMWH). Patients exposed to bovine-derived heparin appear to be at higher risk of HIT than patients exposed to porcine-derived heparin.6 Currently, only porcine-derived heparin is available in the United
Clinical Features of HIT
The diagnosis of HIT can be difficult, if based solely on the development of thrombocytopenia, because cardiac surgical patients have multiple reasons to be thrombocytopenic. Clinical features, such as thrombocytopenia, usually manifest 5 to 10 days after the first dose of heparin.6 The delay in onset after exposure to heparin also applies to patients with a distant history of HIT. During the acute phase of HIT, patients have circulating, active anti-PF4/heparin antibodies with
Clinical Scoring Systems
Acute thrombocytopenia is a common occurrence in cardiovascular surgical patients.5 Several clinical scoring systems have been developed to reduce unnecessary testing and better define the pretest probability of HIT. These include the HIT Expert Probability Score,13 a post-CPB scoring system,14 and the more commonly used Warkentin 4 T's scoring system.15
The HIT Expert Probability Score employed 26 experts’ opinions on the importance of diagnostic variables associated with HIT. The score
Immunoassay
An ideal laboratory test has a high specificity and sensitivity. In the case of HIT diagnosis, both timely and accurate tests results are critical because delays in anticoagulation may increase the risk of thrombotic complications.6 Immunologic assays are usually the first-line test as they are commonly done in hospital laboratories with a relatively short turnaround time. The first test of this kind was the ELISA (enzyme-linked immunosorbent assay), which detects IgG, IgM, and IgA antibodies.19
Diagnostic Algorithm—Putting It All Together
The clinical approach to the patient with thrombocytopenia after cardiac surgery should combine a clinical assessment (usually the 4 T's) and laboratory evaluation. Patients undergoing cardiac surgery should have a daily measurement of platelet count. If the platelet count drops >50% after heparin exposure, the clinician should perform a clinical assessment. Patients assessed as intermediate or high risk for HIT should have the laboratory test performed, including immunoassay and functional
Prevention of HIT
Most of the clinical trials have targeted treatment of HIT once diagnosed or prevention of antibody development in patients with a history of HIT. Some institutions have developed strategies to minimize exposure to unfractionated heparin. It is reasonable to consider LMWH as a first-line agent for venous thromboembolism prophylaxis because this has been shown to reduce the incidence of HIT. A recent Cochrane meta-analysis concluded that 2 cases of HIT could be avoided for every 100 people
Treatment of HIT
After diagnosis of HIT, prompt treatment is essential to interrupt the prothrombotic cascade by eliminating all exposure to heparin and heparin-containing products and rapidly initiating alternate anticoagulants. Practitioners must be particularly vigilant for less obvious sources of heparin exposure, such as heparin-containing intravenous flushes and heparin-coated indwelling catheters or circuits. An alternative anticoagulant should be administered to achieve therapeutic anticoagulation to
Platelet Transfusion in HIT
Because thrombocytopenia is a hallmark of HIT, the question arises whether to treat the existing thrombocytopenia with platelet transfusions. Counterintuitively, spontaneous bleeding is not common despite the low platelet counts and treatment with alternative anticoagulants.39 Initial reports suggested that platelet transfusions in this setting exacerbated the thrombotic sequelae without the expected increase in platelet counts.51, 52 More recently, a series of patients with a high suspicion of
CPB After a Diagnosis of HIT
Often, patients with a history of prior HIT will require cardiac surgery with CPB. In these patients with a remote history of HIT, further testing should be performed before the planned surgery. As described above, ELISA testing for PF4 antibodies is completed first. In the patient with a remote history of HIT, the findings of a normal platelet count and a negative immunologic assay imply that heparin can be given safely for surgery.54 The standard for patients with positive immunologic testing
Management of Other Cardiac Surgeries/Procedures After Diagnosis of HIT
Patients with HIT may require other procedures for which heparin is traditionally part of the treatment protocol. For patients undergoing percutaneous intervention, a meta-analysis by Lee et al. found that bivalirudin had a high procedural success rate and a low risk of major bleeding.71 Likewise, bivalirudin has been used in transcatheter aortic valve implantation procedures with an initial bolus dose, followed by a continuous infusion to maintain the ACT >250.72 Case reports demonstrate the
Conclusion
HIT is a rare but serious risk after cardiac surgery. Early detection is critical to reduce morbidity and mortality. Clinical assessment combined with laboratory evaluation should guide the diagnostic evaluation. Functional assays should be used in addition to immunoassay to diagnose HIT. DTIs are used in the acute phase of the disease with plasma exchange offering utility in select situations. Anticoagulation is recommended after the acute phase of HIT has resolved, commonly with a bridge of
References (76)
- et al.
Heparin-induced thrombocytopenia: A historical perspective
Blood
(2008) - et al.
Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: An analysis of the nationwide inpatient sample
J Cardiothorac Vasc Anesth
(2014) - et al.
Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder
Blood
(2014) - et al.
A 14-year study of heparin-induced thrombocytopenia
Am J Med
(1996) - et al.
Heparin-induced thrombocytopenia in contemporary cardiac surgical practice and experience with a protocol for early identification
Am J Cardiol
(2016) - et al.
Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing vascular surgery
J Cardiothorac Vasc Anesth
(2017) - et al.
Heparin-induced thrombocytopenia and vascular surgery
J Cardiothorac Vasc Anesth
(2017) - et al.
The HIT Expert Probability (HEP) Score: A novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion
J Thromb Haemost
(2010) - et al.
Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass
J Thromb Haemost
(2004) - et al.
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings
J Thromb Haemost
(2006)
Heparin-induced thrombocytopenia: A comprehensive clinical review
J Am Coll Cardiol
Diagnostic value of immunoassays for heparin-induced thrombocytopenia: A systematic review and meta-analysis
Blood
Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery
Am Heart J
Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery
Ann Thorac Surg
Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive
J Thromb Haemost
Determination of serotonin release from platelets by HPLC and ELISA in the diagnosis of heparin-induced thrombocytopenia: comparison with reference method by [C]-serotonin release assay
J Thromb Haemost
Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia
J Thromb Haemost
Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients
J Cardiothorac Vasc Anesth
Heparin-induced thrombocytopenia in patients with ventricular assist devices: Are new prevention strategies required?
Ann Thorac Surg
Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s
Thromb Res
Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172
Blood
Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Chest
A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study
J Thorac Cardiovasc Surg
Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: A propensity score-matched study
Blood
Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia
J Thromb Haemost
Heparin-induced thrombocytopenia and cardiac surgery
Ann Thorac Surg
Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: Results of the CHOOSE-ON trial
Ann Thorac Surg
Update in hematology: heparin-induced thrombocytopenia and bivalirudin
J Cardiothorac Vasc Anesth
IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support
J Thromb Haemost
Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients
J Heart Lung Transplant
One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II
J Thorac Cardiovasc Surg
Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery
J Cardiothorac Vasc Anesth
Bivalirudin for cardiopulmonary bypass in the setting of heparin-induced thrombocytopenia and combined heart and kidney transplantation-diagnostic and therapeutic challenges
J Cardiothorac Vasc Anesth
An assay to monitor bivalirudin levels on cardiopulmonary bypass
Ann Thorac Surg
Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: A meta-analysis of randomized clinical trials
Int J Cardiol
Transfemoral transcatheter aortic valve replacement in a patient with heparin-induced thrombocytopenia: Intraoperative anticoagulation management with bivalirudin (angiomax)
J Cardiothorac Vasc Anesth
Pulmonary endarterectomy under hypothermic circulatory arrest in a patient with heparin-induced thrombocytopenia
J Cardiothorac Vasc Anesth
Heparin-induced thrombocytopenia in intensive care patients
Crit Care Med
Cited by (12)
Heparin-Induced Thrombocytopenia in Patients With Mechanical Circulatory Support
2022, Journal of Cardiothoracic and Vascular AnesthesiaThrombocytopenia: Perioperative Considerations for Patients Undergoing Cardiac Surgery
2022, Journal of Cardiothoracic and Vascular AnesthesiaCitation Excerpt :Therefore, strategies to allow for heparin reexposure during cardiopulmonary bypass frequently are employed. In patients with a remote history of HIT type 2, it is estimated that the duration of antibody circulation is typically <90 days.114 For patients needing cardiac surgery, with a prior diagnosis of HIT type 2, ELISA testing for heparin/PF4 antibody presence should be performed, which, if negative, should allow for single-dose heparin exposure for CPB.114
Pulmonary protection and respiratory support
2022, Cardiopulmonary Bypass: Advances in Extracorporeal Life SupportHow I treat anemia in the perisurgical setting
2020, BloodCitation Excerpt :Attention was made to maintain body temperature, correct acidosis, and monitor for coagulopathy and excessive postsurgical blood loss (and none was noted). Laboratory results obtained 24 hours after the surgery (Table 1) were consistent with anemia of acute blood loss and postcardiac bypass–associated thrombocytopenia.26 There was no acute need for ESA but restoration of iron levels remained a priority.
Efficacy of arteriovenous argatroban versus heparin flush anticoagulation after cardiovascular surgery
2023, National Medical Journal of ChinaPotential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review
2023, Russian Journal of Cardiology